Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline for vaping cessation
NCT05431387Phase 2Completed
- Sponsor
- Achieve Life Sciences
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cytisinicline in nicotine dependence, sponsored by Achieve Life Sciences. Started Jul 2022; status: completed.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05431387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431387.